Standout Papers

Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-... 2002 2026 2010 2018 951
  1. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses (2004)
    Paulo C. Rodrı́guez, David Quiceno et al. Cancer Research
  2. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase (2002)
    David H. Munn, Madhav Sharma et al. Science
  3. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes (2004)
    David H. Munn, Madhav Sharma et al. Journal of Clinical Investigation
  4. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (2016)
    Matthew D. Hellmann, Naiyer A. Rizvi et al. The Lancet Oncology
  5. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (2018)
    Matthew D. Hellmann, Margaret K. Callahan et al. Cancer Cell
  6. Lipid accumulation and dendritic cell dysfunction in cancer (2010)
    Donna L. Herber, Wei Cao et al. Nature Medicine
  7. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study (2018)
    Scott Gettinger, Leora Horn et al. Journal of Clinical Oncology
  8. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study (2016)
    Scott Antonia, Sarah B. Goldberg et al. The Lancet Oncology
  9. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
    Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology
  10. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology
  11. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology
  12. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
    Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology
  13. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial (2017)
    Michele Maio, Arnaud Scherpereel et al. The Lancet Oncology
  14. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies (2022)
    Antonio Passaro, Julie R. Brahmer et al. Journal of Clinical Oncology

Immediate Impact

24 by Nobel laureates 15 from Science/Nature 178 standout
Sub-graph 1 of 18

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
27 intermediate papers

Works of Scott Antonia being referenced

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
2022 Standout
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
2018
and 29 more

Author Peers

Author Last Decade Papers Cites
Scott Antonia 13098 5776 8615 345 20.1k
Omid Hamid 20826 4792 9634 407 25.6k
Jason J. Luke 7975 2083 4708 290 12.6k
Suzanne Ostrand‐Rosenberg 10648 1843 17394 156 23.9k
Patrick Hwu 9200 1563 9802 219 15.5k
Matteo S. Carlino 9269 1938 3616 299 12.0k
Kunle Odunsi 7032 1432 8005 361 15.1k
Padmanee Sharma 19463 5594 13562 254 27.6k
Catherine Sautès‐Fridman 14429 5056 15615 300 28.2k
Gavin P. Dunn 8231 1767 8781 135 15.9k
Bart Neyns 9568 2557 4325 310 13.5k

All Works

Loading papers...

Rankless by CCL
2026